Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Executive summary

Conclusions

1 evidence topic · 13 sources

Summary: conclusions for formulary review
  • Rinzimetostat (ORIC-944) is an investigational oral allosteric inhibitor of PRC2 that binds the EED subunit. ORIC states that it has “not submitted for, or obtained, regulatory approval for any product candidate”, and no source states a submission or launch timing. No brand name, dosage strength, wholesale acquisition cost, or average sales price has been published.
  • The population is men with mCRPC whose disease progressed on abiraterone. ORIC estimates an annual U.S. incidence of approximately 17,000 men in this population; no peer-reviewed estimate of this number was identified. ARPI use before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023 in a U.S. cohort of 5,361 men, and median overall survival in U.S. real-world mCRPC cohorts ranged from 24.6 to 27.2 months.
  • All clinical data on rinzimetostat are company-reported results of the phase 1/1b ORIC-944-01 study, released in press releases, investor presentations, and SEC filings; no peer-reviewed publication or congress abstract of rinzimetostat clinical results was identified. In the darolutamide dose-optimization cohort receiving 400 mg after abiraterone (18 participants), ORIC reported landmark rPFS rates of 93%, 84%, and 84% at 3, 4, and 5 months as of March 6, 2026, with a median follow-up of 4.9 months and median rPFS “Not mature”; confirmed PSA50 response in 5 of 15 participants (33%) at the January 16, 2026 cutoff; and MR50 in 10 of 14 participants (71%) with detectable baseline ctDNA. These are single-arm results without a concurrent control.
  • In the same 400 mg cohort, ORIC reported fatigue in 39%, diarrhea in 22%, and nausea in 22% of participants, a single grade 3 treatment-related adverse event (6%), no serious treatment-related adverse events, and discontinuations in 6%. One grade 4 acute kidney injury was reported in the wider post-ARPI safety set of 72 participants. ORIC selected 400 mg once daily with darolutamide 600 mg twice daily as the recommended phase 3 dose after an exposure-response analysis of 113 participants.
  • Himalayas-1 (NCT07723248) is a randomized, open-label phase 3 trial of approximately 600 participants comparing rinzimetostat plus darolutamide with physician’s choice of darolutamide, enzalutamide, or docetaxel. Its primary endpoint is rPFS by BICR, overall survival is the key secondary endpoint, and the registry lists an estimated primary completion in March 2028. No results have been released.
  • Darolutamide, the partner drug, is labeled for nmCRPC and mCSPC; mCRPC is not a labeled indication. Its wholesale acquisition cost is $15,100.80 per 120-tablet bottle, effective 1 January 2026.
  • Mevrometostat, an EZH2 inhibitor, is in a phase 3 trial (MEVPRO-1) in the same post-abiraterone population with the same primary endpoint; in a randomized phase 1 expansion it was associated with a median rPFS of 14.3 months with enzalutamide compared with 6.2 months with enzalutamide alone (hazard ratio 0.51). Tazemetostat was withdrawn from the U.S. market for hematologic second primary malignancies (18 of 318 participants, 5.7%). Comparisons of these agents with rinzimetostat are cross-trial.
  • Evidence gaps for a formulary review are the absence of randomized results, overall survival data, health-related quality of life data, peer-reviewed rinzimetostat data, a price, and any budget impact or cost-effectiveness analysis of rinzimetostat.